Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2021-03-29 / Front Immunol 2021;12:641307High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2020-10-26 / Front Oncol 2020;10:536700Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2020-02-26 / J. Cell. Mol. Med. 2020 Apr;24(7):4286-4297Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
/in Dendritic Cells, International Publications, Prostate Cancer /von 2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-11-14 / J Immunother Cancer 2019 Nov;7(1):302Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy
/in Dendritic Cells, International Publications, Prostate Cancer /von 2019-10-29 / Future Sci OA 2019 Oct;5(10):FSO435Past, Current, and Future of Immunotherapies for Prostate Cancer
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Newcastle Disease Virus, Prostate Cancer /von 2019-09-11 / Front Oncol 2019;9:884Capacitive hyperthermia as an alternative to brachytherapy in DNA damages of human prostate cancer cell line (DU-145)
/in Hyperthermia, International Publications, Prostate Cancer /von 2018-10-25 / Int. J. Radiat. Biol. 2019 Feb;95(2):193-200Potentiating prostate cancer immunotherapy with oncolytic viruses
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2018-02-13 / Nat Rev Urol 2018 Apr;15(4):235-250
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus
- Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
- A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma